IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v13y2012i5p651-661.html
   My bibliography  Save this article

Genetic testing in the European Union: does economic evaluation matter?

Author

Listed:
  • Fernando Antoñanzas
  • R. Rodríguez-Ibeas
  • M. Hutter
  • R. Lorente
  • C. Juárez
  • M. Pinillos

Abstract

Economic evaluation of genetic technologies matters but the number of published studies is still rather low as to be widely used for most of the decisions in different jurisdictions across the EU. Further, the decision bodies across EU27 are fragmented and the responsibilities are located at different levels of the decision process for what it is difficult to find out whether a given decision on genetic tests was somehow supported by the economic evaluation results. Copyright Springer-Verlag 2012

Suggested Citation

  • Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos, 2012. "Genetic testing in the European Union: does economic evaluation matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 651-661, October.
    • Handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:651-661
    DOI: 10.1007/s10198-011-0319-x
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-011-0319-x
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-011-0319-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Rogowski, Wolf, 2007. "Current impact of gene technology on healthcare: A map of economic assessments," Health Policy, Elsevier, vol. 80(2), pages 340-357, February.
    2. Wolf H. Rogowski, 2009. "The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study," Medical Decision Making, , vol. 29(2), pages 224-238, March.
    3. Randi Nielsen & Dorte Gyrd‐Hansen, 2002. "Prenatal screening for cystic fibrosis: an economic analysis," Health Economics, John Wiley & Sons, Ltd., vol. 11(4), pages 285-299, June.
    4. Cam Donaldson & Phil Shackley & Mona Abdalla, 1997. "Using Willingness To Pay To Value Close Substitutes: Carrier Screening for Cystic Fibrosis Revisited," Health Economics, John Wiley & Sons, Ltd., vol. 6(2), pages 145-159, March.
    5. Serra-Prat, M. & Gallo, P. & Jovell, A.J. & Aymerich, M. & Dolors Estrada, M., 1998. "Trade-offs in prenatal detection of down syndrome," American Journal of Public Health, American Public Health Association, vol. 88(4), pages 551-557.
    6. Cam Donaldson & Phil Shackley & Mona Abdalla & Zosia Miedzybrodzka, 1995. "Willingness to pay for antenatal carrier screening for cystic fibrosis," Health Economics, John Wiley & Sons, Ltd., vol. 4(6), pages 439-452, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Nævdal, Eric, 2014. "Optimal screening for genetic diseases," Economics & Human Biology, Elsevier, vol. 15(C), pages 129-139.
    2. F. Antoñanzas & C. Juárez-Castelló & R. Rodríguez-Ibeas, 2015. "Some economics on personalized and predictive medicine," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 985-994, December.
    3. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2015. "Is personalized medicine a panacea for health management? Some thoughts on its desirability," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(5), pages 455-457, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rogowski, Wolf H. & Schleidgen, Sebastian, 2015. "Using needs-based frameworks for evaluating new technologies: An application to genetic tests," Health Policy, Elsevier, vol. 119(2), pages 147-155.
    2. Klose, Thomas, 1999. "The contingent valuation method in health care," Health Policy, Elsevier, vol. 47(2), pages 97-123, May.
    3. Mataria, Awad & Donaldson, Cam & Luchini, Stephane & Moatti, Jean-Paul, 2004. "A stated preference approach to assessing health care-quality improvements in Palestine: from theoretical validity to policy implications," Journal of Health Economics, Elsevier, vol. 23(6), pages 1285-1311, November.
    4. Bobinac, Ana & van Exel, N. Job A. & Rutten, Frans F.H. & Brouwer, Werner B.F., 2012. "GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation," Journal of Health Economics, Elsevier, vol. 31(1), pages 158-168.
    5. Hall, Jane & Fiebig, Denzil G. & King, Madeleine T. & Hossain, Ishrat & Louviere, Jordan J., 2006. "What influences participation in genetic carrier testing?: Results from a discrete choice experiment," Journal of Health Economics, Elsevier, vol. 25(3), pages 520-537, May.
    6. Peter J. Neumann & Joshua T. Cohen & James K. Hammitt & Thomas W. Concannon & Hannah R. Auerbach & ChiHui Fang & David M. Kent, 2012. "Willingness‐to‐pay for predictive tests with no immediate treatment implications: a survey of US residents," Health Economics, John Wiley & Sons, Ltd., vol. 21(3), pages 238-251, March.
    7. Stéphane Luchini & Christel Protière & Jean‐Paul Moatti, 2003. "Eliciting several willingness to pay in a single contingent valuation survey: application to health care," Health Economics, John Wiley & Sons, Ltd., vol. 12(1), pages 51-64, January.
    8. Yan Meng & Philip M. Clarke & Ilias Goranitis, 2022. "The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions," PharmacoEconomics, Springer, vol. 40(2), pages 215-223, February.
    9. Shackley, Phil & Donaldson, Cam, 2002. "Should we use willingness to pay to elicit community preferences for health care?: New evidence from using a 'marginal' approach," Journal of Health Economics, Elsevier, vol. 21(6), pages 971-991, November.
    10. Ryan, Mandy & Scott, David A. & Donaldson, Cam, 2004. "Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods," Journal of Health Economics, Elsevier, vol. 23(2), pages 237-258, March.
    11. Cam Donaldson & Helen Mason & Phil Shackley, 2012. "Contingent Valuation in Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 40, Edward Elgar Publishing.
    12. Ryan, Mandy & San Miguel, Fernando, 2000. "Testing for consistency in willingness to pay experiments," Journal of Economic Psychology, Elsevier, vol. 21(3), pages 305-317, June.
    13. Anna García‐Altés, 2001. "Twenty years of health care economic analysis in Spain: are we doing well?," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 715-729, December.
    14. Richard D. Smith, 2003. "Construction of the contingent valuation market in health care:a critical assessment," Health Economics, John Wiley & Sons, Ltd., vol. 12(8), pages 609-628, August.
    15. Alan Diener & Bernie O'Brien & Amiram Gafni, 1998. "Health care contingent valuation studies: a review and classification of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 7(4), pages 313-326, June.
    16. Alan Shiell & Lisa Gold, 2003. "If the price is right: vagueness and values clarification in contingent valuation," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 909-919, November.
    17. Maximilian Hatz & Katharina Schremser & Wolf Rogowski, 2014. "Is Individualized Medicine More Cost-Effective? A Systematic Review," PharmacoEconomics, Springer, vol. 32(5), pages 443-455, May.
    18. Wolf Rogowski & Katherine Payne & Petra Schnell-Inderst & Andrea Manca & Ursula Rochau & Beate Jahn & Oguzhan Alagoz & Reiner Leidl & Uwe Siebert, 2015. "Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation," PharmacoEconomics, Springer, vol. 33(1), pages 49-59, January.
    19. Powdthavee, Nattavudh & van den Berg, Bernard, 2011. "Putting different price tags on the same health condition: Re-evaluating the well-being valuation approach," Journal of Health Economics, Elsevier, vol. 30(5), pages 1032-1043.
    20. Cam Donaldson & Phil Shackley & Mona Abdalla, 1997. "Using Willingness To Pay To Value Close Substitutes: Carrier Screening for Cystic Fibrosis Revisited," Health Economics, John Wiley & Sons, Ltd., vol. 6(2), pages 145-159, March.

    More about this item

    Keywords

    Genetic tests; Economic evaluations; Decision-making process; EU27; I18; I12;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • I12 - Health, Education, and Welfare - - Health - - - Health Behavior

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:651-661. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.